Related Experiment Videos
Phase II trial of mitoxantrone in head and neck cancer
Investigational New Drugs
|January 1, 1984
Abstract:
Mitoxantrone (1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.
Insights
Mitoxantrone, an aminoanthraquinone, shows promise in treating advanced head and neck cancers. A phase II trial evaluated this chemotherapy agent on a three-week dosing schedule for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Mitoxantrone is an aminoanthraquinone derivative.
- It has demonstrated clinical activity in breast cancer, lymphoma, and leukemia.
- The efficacy of mitoxantrone in head and neck cancers requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of mitoxantrone in patients with advanced head and neck cancers.
- To assess the safety and tolerability of mitoxantrone using a specific dosing schedule.
Main Methods:
- A phase II clinical trial was conducted.
- Patients with advanced head and neck cancers received mitoxantrone every three weeks.
Main Results:
- Preliminary data suggests potential clinical activity of mitoxantrone.
- Further analysis is needed to determine response rates and survival benefits.
Conclusions:
- Mitoxantrone may be a viable treatment option for advanced head and neck cancers.
- Additional research is warranted to confirm these findings and optimize treatment protocols.